1 1 3 2 VOLUME 22 | NUMBER 10 | OCTOBER 2016 nature medicine both as a sponge for the let-7 family of microRNAs during muscle differentiation 31 and as a modifier of histone H3 methylation during embryonic development 32 . These results implicate divergent functions of lncRNAs in different pathophysiological settings to coordinate epigenetic reprogramming in the heart.
Here we identify a cardiac-enriched lncRNA, Chaer, which is both necessary and sufficient for cardiac hypertrophy and induction of genes involved in hypertrophy (hereafter referred to as hypertrophic gene expression), through its interaction with the enhancer of zeste homolog 2 (EZH2) subunit of PRC2.
RESULTS
The lncRNA Chaer is necessary for cardiac hypertrophy From the transcriptomic analysis of pressure-overload-induced failing hearts in mice, we identified nearly 150 lncRNAs that are significantly de-regulated 22 . One of these lncRNAs is a 2,737-nt transcript derived from a two-exon gene located on chromosome 5 of the mouse genome that shows highly enriched expression in heart ( Fig. 1a,b) . Moreover, its expression was progressively decreased in the failing heart after transaortic constriction (TAC) surgery ( Supplementary  Fig. 1a ). Based on its function, as studied below, we named this lncRNA cardiac-hypertrophy-associated epigenetic regulator (Chaer). Translational analysis failed to find any major open-reading frames (ORFs) with translational propensity (Fig. 1a, bottom) . By using an in vitro translation assay in the presence of puromycin, we confirmed that, similarly to Hotair, no significant translation events could be detected for Chaer RNA (Fig. 1c) . In addition, none of the predicted small peptides that could potentially be derived from the putative small ORFs in Chaer transcript were detected in the mass spectrum data set from PFAM 27.0 (ref. 33) . Northern blot analysis identified conserved Chaer transcripts in mouse, rat and human hearts as a single band (2.7 kb for mouse and rat Chaer; ~2 kb for its human homolog; Supplementary Fig. 1b-d) . Expression analysis in primary cardiomyocytes and fibroblasts isolated from mouse hearts showed that Chaer was specifically expressed in cardiomyocytes but not in fibroblasts (Supplementary Fig. 1e) . A subcellular fractionation assay detected Chaer predominantly in the nuclear fraction, similar to the localization pattern observed for Hotair (Supplementary Fig. 1f ). This subcellular localization was further supported by imaging Chaer RNA with fluorescent in situ hybridization (FISH) in mouse heart tissue ( Supplementary Fig. 2) .
To determine the functional role of Chaer, we used a CRISPR-Cas9mediated genome-editing approach to inactivate Chaer in C57BL/6 mice by deleting exon 2, which contains the majority of the transcript (Fig. 1d) . Genomic deletion and loss of the Chaer transcript in the heart from the knockout (Chaer-KO) mice was validated by genomic DNA PCR ( Fig. 1e) and northern blot analysis (Supplementary Fig. 1b) . Under basal conditions, we did not observe any morphological or functional phenotype in Chaer-KO hearts on the basis of histology, echocardiography and marker gene expression ( Fig. 1f-j) . However, cardiac hypertrophy in response to pressure overload following TAC surgery was significantly attenuated in Chaer-KO mice (Fig. 1f,g) . Moreover, pathological fibrosis after TAC was significantly blunted in Chaer-KO hearts (Fig. 1h,i) , and cardiac function was preserved ( Fig. 1j, Supplementary Fig. 3 and Supplementary Table 1 ).
To further study how Chaer contributes to cardiac hypertrophy, we used a Chaer-specific siRNA (siChaer) to achieve ~70% knockdown of its expression in isolated neonatal rat ventricular myocytes (NRVMs). Chaer knockdown did not change myocyte morphology under basal conditions, but it significantly suppressed hypertrophic growth induced by phenylephrine (PE, 50 µM; Fig. 2a and Supplementary  Fig. 4a ). In contrast, NRVMs with Chaer overexpression showed a significantly enlarged cell size as compared to that of control cells ( Fig. 2b and Supplementary Fig. 4b ). PE induction of hypertrophic gene expression, including that for natriuretic peptide type A (Nppa, also known as Anf), β-myosin heavy chain (Myh7) and skeletal muscle α-actin (Acta1), was markedly attenuated after Chaer knockdown ( Supplementary Fig. 4c ), whereas Chaer overexpression substantially increased their expression in the absence of PE stimulation, except that the effect for Anf did not reach significance ( Supplementary  Fig. 4d ). In addition, expression of the gene neighboring Chaer, HOP homeobox (Hopx), was not affected by Chaer inactivation or overexpression, suggesting that Chaer functions independently of a Hopxmediated cis mechanism ( Supplementary Fig. 4c,d) . These in vivo and in vitro data indicate that Chaer is necessary and sufficient for cardiomyocyte hypertrophy and pathological gene expression.
Chaer negatively regulates PRC2 function during hypertrophy
To investigate the molecular mechanisms underlying Chaer function in cardiomyocytes, we performed RNA sequencing (RNA-seq) analysis in cardiomyocytes with or without Chaer knockdown under basal and hypertrophic stimulation. Clustering analysis revealed that for 48.3% of the genes whose expression was changed by PE treatment (>1.5-fold), the effect of PE treatment was markedly reversed by Chaer knockdown (Supplementary Fig. 5a (left),5b (top)); moreover, for 68.8% of the genes whose expression was affected by Chaer deficiency (>1.5-fold), their expression was oppositely regulated by PE treatment ( Supplementary Fig. 5a (right),5b (bottom)). Cardiomyopathyrelated and cell-cycle-related genes were enriched in the genes whose expression was negatively correlated between the conditions of Chaer deficiency and PE treatment ( Supplementary Tables 2 and 3) . This observation suggests a broad effect of Chaer-mediated regulation on transcriptome reprogramming during hypertrophy. Notably, 27 of the top 50 downregulated genes following Chaer knockdown were clustered in 11 genomic loci ( Supplementary Table 4 ), including the imprinted gene H19 (Supplementary Fig. 5c-e ), implicating Chaer-mediated chromatin remodeling in transcriptome reprogramming. Histone methylation has been implicated in transcriptome reprogramming during cardiac hypertrophy and heart failure [7] [8] [9] . Indeed, we observed a dynamic change in global histone methylation at H3K9 and H3K27 sites, but not at H3K4 sites, following PE treatment in NRVMs (Supplementary Fig. 5f ). Chaer deficiency in cardiomyocytes specifically increased di-and trimethylation at H3K27 without affecting the levels of dimethylation at H3K4 (H3K4me2) or H3K9 (H3K9me2) sites ( Fig. 2c) , whereas Chaer overexpression specifically reduced H3K27 trimethylation without detectable effect on other types of histone methylation (Fig. 2d) . These data imply a specific and negative regulation of H3K27 methylation by Chaer in cardiomyocytes.
Di-and trimethylation at H3K27 are catalyzed by the histone methyltransferase PRC2, which is a well-known molecular target of several regulatory lncRNAs 25, 34 . Using an RNA immunoprecipitation (RIP) assay, we detected a dramatic enrichment of Chaer in immunoprecipiates with the PRC2 components SUZ12 and EZH2, but not with the TrxG-MLL components WDR5 or LSD1. As a control, Hotair was detected to interact with both PRC2 and LSD1, as previously reported 29 ( Fig. 2e) . Of note, Chaer knockdown in cardiomyocytes markedly augmented the interaction between PRC2 and Hotair or Fendrr 21 without changing the total expression levels of these lncRNAs ( Supplementary Fig. 6a,b) . Conversely, Chaer overexpression in npg a r t i c l e s nature medicine VOLUME 22 | NUMBER 10 | OCTOBER 2016 1 1 3 3 mouse embryonic fibroblasts (MEFs), in which no endogenous Chaer was expressed, markedly reduced the interaction of Hotair or Fendrr with PRC2, even though the total expression levels of these lncRNAs were increased ( Supplementary Fig. 6c,d) . To further demonstrate the functional effect of the Chaer-PRC2 interaction, we examined the effect of Chaer on H19 expression, a well-established target whose expression is suppressed by a lncRNA-PRC2 complex. In contrast to the inhibitory effect of Hotair, Chaer expression markedly induced H19 expression in MEFs, whereas overexpression of Hotair competed with and blocked Chaer-induced H19 expression ( Supplementary  Fig. 6e ). Taken together, these data suggest that the interaction of Chaer with PRC2 antagonizes PRC2 binding to other lncRNAs and relieves the suppressive function of PRC2 on target genes, an effect distinct from other known PRC2-binding lncRNAs.
The molecular basis of Chaer-mediated PRC2 regulation
To further characterize the Chaer-PRC2 interaction at a molecular level, we conjugated a modified streptavidin-binding S1 RNA tag (S1m) 35 with full-length or truncated fragments of Chaer (Supplementary Fig. 7 ). All constructs were expressed in MEFs at similar levels ( Supplementary Fig. 7) . We then used streptavidinconjugated beads in protein pulldown experiments. As compared to the negative controls (including the blank, untagged wild-type (WT) Chaer and tagged EGFP), tagged full-length Chaer specifically pulled down EZH2 but not the SUZ12, RbAp46, RbAp48 or EED components of the PRC2 complex ( Fig. 2f) . On the basis of the results with the truncated fragments, several regions in Chaer (including nt 2,166-2,737 and nt 1,059-1,666) were identified to be necessary for its interaction with EZH2. However, only one 524-nt region (Chaer(∆525-2737)) near the 5′ end of Chaer was found to be both necessary and sufficient for EZH2 binding (Fig. 2f) . Expression of this fragment alone was sufficient to increase the expression of H19 and the muscle-specific gene Acta1 in MEFs to the same levels as did expression of full-length Chaer, whereas expression of a similar-sized fragment of Chaer without the EZH2-binding region (Chaer(∆0-505)) showed no effect ( Fig. 2g) .
Within the 5′ 524-nt fragment, we identified a 66-nt motif with a predicted secondary structure of two connected stem-loops, with four nucleotides in each loop (termed a bi-tetra-loop), similar to a previously validated 89-mer EZH2-EED-interacting motif in Hotair 36 , and a 56-mer motif found in Fendrr. The secondary structure of this motif is conserved among mouse, rat and human Chaer homologs ( Fig. 3a and Supplementary Fig. 8a-c) . Several differences in the sequences of the predicted stem structures are present between the mouse and rat homologs; however, these differences are paired and do not affect the predicted stem structures ( Fig. 3a) . To demonstrate the direct interaction between this motif and PRC2, we performed an RNA electrophoresis mobility shift assay (EMSA) and detected a specific complex between the Chaer 66-mer and recombinant EZH2 (Fig. 3b) . This interaction was effectively competed by the EZH2binding motifs from either Chaer or Hotair, supporting the notion of a similar binding interaction for these two lncRNAs (Fig. 3b) . However, the EZH2-binding motif from Chaer showed lower binding affinity than the motif from Hotair (Fig. 3c) . Moreover, a bindingpropensity analysis revealed a similar predicted interaction pattern in the EZH2 RNA-binding region of Chaer and Hotair ( Fig. 3d and Supplementary Fig. 8d ). These data suggest that Chaer possesses a potential EZH2-binding motif with shared features to the PRC2binding motif in Hotair.
Regulation of the Chaer-PRC2 interaction by hypertrophic signals
Although Chaer negatively regulates PRC2 function through a direct interaction in cells, it did not directly affect the enzymatic activity of PRC2 in vitro (Fig. 4a) . However, a chromatin immunoprecipitation (ChIP) assay with an EZH2-specific antibody revealed that Chaer overexpression in MEFs led to reduced binding of PRC2 to the H19 promoter ( Supplementary Fig. 9a ), suggesting that Chaer affects PRC2-mediated epigenetic modification by altering its binding at specific gene loci. In support of the concept that Chaer regulates PRC2 function during cardiac hypertrophy, RIP analysis with anti-EZH2 and anti-SUZ12 detected a transient but robust enhancement of Chaer-PRC2 interaction in NRVMs within the first 8 h of PE treatment, which was inversely correlated with the Hotair-PRC2 interaction profile (Fig. 4b) . This early transient interaction preceded a progressive decrease of global H3K27me3 levels ( Supplementary  Fig. 9b ), followed by induction of hypertrophic gene expression ( Supplementary Fig. 9c) . Notably, pre-emptive inactivation of Chaer Figure 2 Chaer negatively regulates H3K27 trimethylation via its interaction with the catalytic subunit of PRC2. (a) Chaer expression in (left), and cell size of (right), control and PE-treated (50 µM) NRVMs with (siChaer) or without (siNeg; negative control siRNA) Chaer knockdown (n = 3 biological replicates)). Data are mean ± s.e.m. *P < 0.05 and **P < 0.01 (versus siNeg); ## P < 0.01 and ### P < 0.001 (versus control); by Student's t-test. (b) Chaer expression in (left), and cell size of (right), NRVMs following infection with a control adenovirus (Ad-lacZ) or one overexpressing Chaer (Ad-Chaer) (n = 3 biological replicates). Data are mean ± s.e.m. ***P < 0.001 by Student's t-test. (c,d) Representative western blot analyses (left) and quantification of H3 methylation (right), as indicated, in NRVMs in which Chaer was knocked down (c) or overexpressed (d) (n = 3 biological replicates). Methylated H3 levels were normalized to total H3 levels. Data are mean ± s.e.m. *P < 0.05 and **P < 0.01; by Student's t-test (versus siNeg (c) or Ad-lacZ (d) controls). (e) RNA immunoprecipitation (RIP) analysis using the antibodies indicated, followed by qRT-PCR for Chaer, Hotair and Hoxa distal transcript antisense RNA (Hottip). Values were normalized to the corresponding normal IgG RIP groups. Data are mean ± s.d. from triplicates with one repeat. (f) Representative western blot analysis (of n = 2) of a tagged-RNA streptavidin pulldown assay. Full-length (WT) Chaer and truncated Chaer mutants, as indicated, were tagged with a modified S1 motif (S1m) and transfected into MEFs for 48 h, followed by streptavidinbead pulldown. PRC2 components including SUZ12, EZH2, retinoblastomaassociated proteins 46 expression substantially blocked the PE-induced reduction in global H3K27me3 levels in cardiomyocytes ( Supplementary Fig. 9d ). Consistent with our observations in MEFs, PRC2 ChIP analysis in NRVMs showed that PE treatment decreased PRC2 binding to the promoter regions of the hypertrophic genes Anf, Myh7 and Acta1 (Fig. 4c) ; moreover, this effect was reversed by Chaer inactivation (Fig. 4d) . Overexpression of Chaer in NRVMs was sufficient to reduce PRC2 targeting to these genes ( Fig. 4e) . Chaer knockdown reversed the PE-triggered reduction of H3K27me3 levels at the hypertrophic genes ( Fig. 4f,g) , whereas Chaer overexpression substantially decreased H3K27me3 levels ( Fig. 4h) . Finally, to demonstrate that Chaer-mediated gene regulation was dependent on PRC2 activity, we tested the effect of the EZH2 inhibitor GSK126 (1 µM) in PE-treated NRVMs (Fig. 4i) . Indeed, PRC2 inhibition abolished the effect of Chaer knockdown on hypertrophic gene expression (significant for Myh7 and Acta1, and a trend for Anf) in PE-treated NRVMs (Fig. 4j) . These data establish that a transiently enhanced interaction between Chaer and PRC2 at the onset of hypertrophic stimulation in cardiomyocytes is both necessary and sufficient to release pathological gene suppression by H3K27 trimethylation. The transient interaction between Chaer and the PRC2 complex after hypertrophic stimulation indicates that a dynamic signaling cascade is involved in this process. Concurrent with the enhanced Chaer-PRC2 interaction, the mTOR signaling pathway, as assessed by downstream ribosomal protein S6 kinase (S6K) phosphorylation 37 , was rapidly activated following PE treatment in NRVMs ( Fig. 5a and Supplementary  Fig. 10a ). Indeed, mTOR inhibition by either rapamycin (Fig. 5b) or amino acid starvation 38 (Supplementary Fig. 10b ) completely blocked the PE-induced enhancement of the Chaer-PRC2 interaction (Fig. 5c,d and Supplementary Fig. 10c ). Conversely, re-feeding of the aminoacid-starved NRVMs dramatically enhanced the Chaer-PRC2 interaction in a rapamycin-sensitive manner (Supplementary Fig. 10d) . Moreover, mTOR inhibition significantly reversed the decrease in global H3K27me3 levels in response to PE treatment ( Fig. 5b) and suppressed PE-induced hypertrophic gene expression ( Fig. 5e) . These data suggest that the enhancement of the Chaer-PRC2 interaction by hypertrophic stimulation is a specific and mTOR-dependent event.
Two distinct mammalian target of rapamycin complexes (mTORCs) exist, namely mTORC1 and mTORC2, which are specified, respectively, by the presence of either regulatory-associated protein of mTOR (Raptor) 39 or rapamycin-insensitive companion of mTOR (Rictor) 40 .
To test which complex contributes to the Chaer-mediated hypertrophic transition, we knocked down the expression of Raptor or Rictor in NRVMs using specific siRNAs (Fig. 5f) . Inactivation of Raptor, but not Rictor, completely abolished the enhanced Chaer-PRC2 interaction after PE treatment (Fig. 5g) . In line with this observation, PE-induced expression of Anf, Myh7 and Acta1 was significantly suppressed by Raptor knockdown but was even further enhanced by Rictor knockdown (Fig. 5h) . Finally, Chaer overexpression partially reversed the effects of rapamycin treatment ( Supplementary  Fig. 10e ) and Raptor knockdown ( Supplementary Fig. 10f ) in repressing hypertrophic gene expression, suggesting a cross-talk between mTORC1 and the Chaer-PRC2 interaction in mediating cardiomyocyte hypertrophic gene expression.
A Chaer-mediated epigenetic checkpoint for cardiac hypertrophy To study the Chaer-PRC2 pathway in vivo, we further analyzed the effect of Chaer inactivation on epigenetic modulation in the mouse heart. After TAC surgery, global H3K27me2 and H3K27me3 levels were significantly increased in hearts from Chaer-KO mice (hereafter referred to as Chaer-KO hearts), with no significant changes observed for H3K9me2 or H3K9me3 levels (Fig. 6a) . ChIP analysis showed that H3K27me3 levels at the promoter regions of Anf, Myh7 and Acta1 were dramatically reduced at 2 weeks after TAC surgery in WT hearts, but were significantly increased in Chaer-KO hearts (Fig. 6b) . Similar to what we observed in vitro, the Chaer-PRC2 interaction in the heart showed a dramatic but transient enhancement as early as 1 h after TAC surgery, and this began to diminish 4 h later (Fig. 6c) . To investigate the significance of the early onset of the Chaer-PRC2 interaction, we used a nanoparticle-mediated transfection method 41 to deliver a chemically modified siChaer into the heart, which achieved an effective silencing of Chaer expression within the experimental time frame (Supplementary Fig. 11a ). By using two delivery strategies, with siRNA injection before (protocol 1) or after (protocol 2) TAC surgery ( Fig. 6d and Supplementary  Fig. 11b,c) , we observed that pre-emptive Chaer knockdown in the npg heart significantly suppressed cardiac hypertrophy and resulted in preserved cardiac function and decreased fibrotic remodeling (Fig. 6e,f  and Supplementary Fig. 11d-f) . Moreover, hypertrophic gene expression was also significantly blunted, in line with an attenuated reduction of H3K27me3 levels at their promoter regions (Fig. 6g,h) .
These results further support the essential role of the Chaer-PRC2 interaction in epigenetic regulation during cardiac hypertrophy.
In marked contrast, delivery of the same Chaer-specific siRNA 1 d after TAC surgery failed to affect the progression of cardiac hypertrophy, despite a comparable level of Chaer silencing ( Fig. 6f and  Supplementary Fig. 11b) . These data reveal a critical time window immediately following the onset of pathological stress, in which an epigenetic checkpoint controls the progression of cardiac hypertrophy and pathological remodeling.
Chaer-PRC2 interaction and regulation in human cardiomyocytes
Expression of the human CHAER transcript was readily detected in human heart (Supplementary Fig. 1d ). Using two independent pairs of primers, we detected an increase of CHAER expression in hearts from individuals with dilated cardiomyopathy, as compared to nondiseased control hearts, although this difference was not significant owing to large variations in CHAER levels ( Supplementary  Fig. 12a ). To study CHAER function in human cardiomyocytes, we first performed RIP analysis using anti-EZH2 in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). We found that CHAER specifically interacted with EZH2 in a rapamycinsensitive manner (Supplementary Fig. 12b ). Next, by using nanoparticle-mediated transfection of human CHAER into hiPSC-CMs, we observed that CHAER overexpression led to an increased expression of the hypertrophic genes ANF, MYH7 and ACTA1 ( Supplementary  Fig. 12c,d) . To test the functional conservation of Chaer, we expressed human CHAER in rat myocytes (Supplementary Fig. 12e ). Similar to mouse Chaer overexpression, human CHAER overexpression in NRVMs increased hypertrophic gene expression ( Supplementary  Fig. 12f) . Moreover, overexpression of mouse Chaer in NRVMs rescued the suppression on PE-induced expression of hypertrophic genes caused by knockdown of endogenous (rat) Chaer ( Supplementary  Fig. 12g-i) . Finally, overexpression of either mouse Chaer or human CHAER in either mouse cells (MEFs) or human cells (HEK293 cells) led to a similar induction of H19 expression ( Supplementary  Fig. 12j-m) . Taken together, these data suggest that Chaer has a conserved gene regulatory function across rodent and human species.
DISCUSSION
Similar to protein-coding genes, lncRNAs contribute markedly to tissue-specific responses, at least in part via epigenetic regulation 22, 42 .
Genome-wide analysis of histone marks has revealed a complex epigenetic landscape that orchestrates gene expression during cardiac hypertrophy 9 . Here we identified a heart-specific lncRNA, Chaer, as a critical regulator of cardiac hypertrophy via its direct interaction with PRC2. This finding, along with other recent reports 21, [25] [26] [27] 30 , identify a class of epigenetic regulatory lncRNAs (referred to as Epi-LncRNAs) in cardiac gene regulation 24 . Other PRC2-interacting lncRNAs, such as Fendrr and Bvht, have been shown to be important in epigenetic programming during heart development 21, 26 . In contrast, the lncRNA Myht regulates cardiac hypertrophy and pathological remodeling through direct interaction with a histone acetylation factor, BRG1 (ref. 30) . Therefore, the effects of Epi-LncRNAs on epigenetic regulation may depend on their interaction with specific protein partners during cardiac development and pathogenesis. Chaer, a cardiacenriched lncRNA, has a hypertrophic signaling-dependent interaction with PRC2 and, as shown by genetic evidence, is essential for cardiac pathological hypertrophy and remodeling in vivo. Elucidation of the molecular basis of lncRNA function is a major challenge in the field. The Chaer transcript contains a bi-tetra-loop Figure 6 Chaer functions as an early checkpoint for TAC-induced hypertrophy in vivo. (a) Immunoblotting analysis (left) and quantification (right) of H3 modifications, as indicated, in WT and Chaer-KO hearts 2 weeks after TAC surgery (n = 3 mice per group). Methylated H3 levels were normalized to total H3 levels. Data are mean ± s.e.m. *P < 0.05 versus WT by Student's t-test. (b) ChIP analysis for H3K27me3 levels at the promoter regions of Anf, Myh7, Acta1 and Gapdh in WT and Chaer-KO hearts from mice that underwent either sham or TAC surgery. Data are mean ± s.d. from triplicates from one mouse per group. (c) Time course of the Chaer-PRC2 interaction, as measured by anti-EZH2 RIP, in a mouse heart after TAC surgery. Data are mean ± s.d. from triplicates from one mouse. (d) Schematic of the two protocols for Chaer inactivation. Two siRNA injections were performed before (protocol 1) or after (protocol 2) TAC surgery. (e,f) Effects of Chaer knockdown in vivo on the weights of the hearts and of the left (LV) and right (RV) ventricles following protocol 1 (e) or protocol 2 (f) in sham-treated mice or in siRNA-expressing mice that underwent TAC surgery (TAC-siNeg or TAC-siChaer) (the numbers of mice tested in each group are indicated in parentheses). Data are mean ± s.e.m. ***P < 0.001 (versus siNeg); # P < 0.05, ## P < 0.01, ### P < 0.001 (versus Sham); by Student's t-test. (g) ChIP analysis for H3K27me3 levels at the promoter regions of Anf, Myh7, Acta1 and Gapdh in the hearts from the sham, TAC-siNeg and TAC-siChaer groups mice treated according to protocol 1. Data are mean ± s.d. from triplicates from one mouse. (h) qRT-PCR analysis for Anf, Myh7 and Acta1 expression in the hearts of the sham, TAC-siNeg and TAC-siChaer groups of mice treated according to protocol 1 (n = 3 mice per group). Data are mean ± s.e.m. *P < 0.05 (versus siNeg); # P < 0.05 (versus Sham); by Student's t-test. npg motif within its 5′ end that is both sufficient and necessary for PRC2 binding. However, the overall structural basis of Chaer function remains speculative and needs to be further investigated. Although the predicted structure of the Chaer PRC2-binding motif shares features with other established PRC2-binding motifs in several EZH2-binding lncRNAs 36 , Chaer binding seems to repress, rather than promote, PRC2 function, as demonstrated for both global and promoter-specific H3K27me3 levels. This negative regulation of PRC2 function is consistent with previous reports that Ezh2 silencing results in cardiac hypertrophy 43, 44 . However, Chaer binding does not seem to directly repress PRC2 enzymatic activity, as assessed by an in vitro assay, but rather probably interferes with PRC2 genomic targeting. Whereas the Chaer-PRC2 interaction is only transiently enhanced at the onset of hypertrophy, the effect of this interaction on downstream H3K27me3 levels seems to be long lasting, given that H3K27me3 levels continue to be suppressed even 2 weeks after TAC surgery. Therefore, Chaer contributes to the timing and specificity of cardiac epigenetic reprogramming during hypertrophy by targeted modulation of histone methylation and de-methylation at the onset of hypertrophic stimulation 45 . It remains to be determined whether the effects of Chaer may also involve other PRC2-binding lncRNAs, such as Hotair, or involve other histone modifiers, such as the H3K27-specific histone demethylases UTX and jumonji domain containing 3 (JMJD3) 46 .
Despite the well-established involvement of the mTOR pathway in cardiac growth, the role of mTOR in the hypertrophic and failing heart remains elusive [47] [48] [49] [50] [51] [52] . One major finding from our study is that the Chaer-PRC2 interaction is a stress-induced transient event that depends on mTOR activity. Previously, cyclin-dependent kinase 1 (CDK1)-mediated phosphorylation of EZH2 (at Thr345) has been shown to enhance the binding affinity of EZH2 with lncRNAs, including Hotair and Xist, during the cell cycle 53 . Although we also observed rapamycin-sensitive EZH2 phosphorylation at Thr345 in PE-treated NRVMs, this phosphorylation occurred at 24 h after PE treatment (data not shown), when the Chaer-EZH2 interaction had already passed its peak. Therefore, other mTORC1-dependent modifications of the PRC2 complex may be involved. Considering the sequence diversity in the binding motifs for PRC2 that are found in different lncRNAs, our findings imply that signaling-dependent modulation of PRC2 may dictate its lncRNA binding partners under different physiological and pathophysiological states, leading to tissue-specific and gene-specific epigenetic reprogramming associated with development and disease. Clearly, more studies are needed to dissect the molecular basis of Chaer-mediated PRC2 regulation in response to hypertrophic signaling.
Although our study focused on the cell-autonomous effects of Chaer on cardiomyocyte hypertrophy, Chaer may also have regulatory effects in non-myocyte cardiac cells. Notably, in the FISH assay we detected a substantial signal for Chaer within the epicardium, where progenitor cells for endothelial cells and fibroblasts have been reported to reside 54 , and Chaer KO hearts had significantly reduced TAC-induced cardiac fibrosis. It is also of note that a substantial number of cell-cycle-related genes are regulated by Chaer. It remains to be determined whether the broad effect of Chaer on cardiac gene expression is mediated through direct effects of epigenetic regulation on gene expression or more indirectly through the secondary effects of master genes under epigenetic regulation.
In summary, our findings reveal a previously uncharacterized epigenetic switch for transcriptome reprogramming at the very beginning of cardiac hypertrophy, involving an mTORC1-dependent interaction between a cardiac-enriched lncRNA, Chaer, and the histone modification complex PRC2. This interaction is a prerequisite for hypertrophic gene expression, cardiac hypertrophy and pathological remodeling. Because the Chaer-PRC2 interaction is transiently induced immediately following stress stimulation, this interaction is not needed for the progression of hypertrophic remodeling beyond the early epigenetic switch point. Considering the functional conservation between rodent and human CHAER, the protective effects of Chaer inactivation in the stressed heart suggest that the Chaer-PRC2 interaction can serve as a potential therapeutic target in the treatment of cardiac hypertrophy and of pathological remodeling in hypertrophic cardiomyopathy.
METHODS
Methods and any associated references are available in the online version of the paper. 
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ONLINE METHODS
Animal and human studies. All experimental procedures involving animals in this study were reviewed and approved by the Institutional Animal Care and Use Committees (IACUCs) of University of California at Los Angeles (UCLA) and conformed to the Guide for the Care and Use of Laboratory Animals, published by the US National Institutes of Health 55 . Experiments with donated human heart tissues were approved by the Ethics Committee Board of Wuhan University, China after obtaining proper informed consent. Male, 8-to 10-weekold mice in the C57BL/6 background were used in this study; the number of mice studied in each experiment is indicated. Mice of different genotypes were randomly assigned to the sham or transaortic constriction (TAC) groups. Echocardiographic analysis was performed by an investigator blinded to the genotype or to the procedure (sham or TAC).
Cell culture, plasmids and adenoviral vectors. Neonatal rat ventricular myocytes (NRVMs) were prepared as previously described 56 and maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 1% insulin-transferrin-selenium (ITS-G, BD Biosciences, CA, USA), 100 U/mL penicillin and 100 µg/mL streptomycin for 24 h before transfection, infection or drug treatment. Immortalized mouse embryonic fibroblasts (MEFs) and human HEK293 cells, authenticated cell lines from ATCC, were maintained in DMEM supplemented with 10% FBS, 2 mM l-glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were provided by D.S. 's lab (University of California, San Francisco) and were prepared and maintained as previously reported 57 . Cardiac fibroblasts were obtained from A.D. 's lab (University of California, Los Angeles) and were prepared as previously reported 58 . Cardiomyocytes from adult mouse heart were isolated using enzymatic digestion as described previously 59 . The lack of mycoplasma contamination of MEFs, NRVMs and HEK293 cells was routinely tested using RT-PCR or a commercial kit. Wild-type Chaer, truncated Chaer mutants and Hotair were cloned from mouse cDNA with Turbo Pfu DNA polymerase (Thermo Fisher Scientific, MA, USA) and inserted into the pcDNA5-CMV vector (Thermo Fisher Scientific, MA, USA) for transient overexpression. Human CHAER was cloned from donated normal human heart tissues into the pcDNA5-CMV vector and overexpressed in NRVMs with nanoparticle-mediated transfection following the manufacturer's instructions (Altogen). Wild-type Chaer and lacZ were cloned into pShuttle-CMV and recombined with pAdeasy-1 to generate adenoviruses expressing Chaer (Ad-Chaer) and lacZ (Ad-lacZ). Chaer 66-mer motif and Hotair 89-mer motif were cloned into pBluescript II for in vitro transcription. Mouse Ezh2 was cloned into pT7CFE1 for in vitro-coupled transcription and translation. Lipofectamine 2000 (Life Technologies, NY, USA) was used to transfect plasmids into MEFs. Negative-control siRNA (siNeg; CMSINC-30; Bioland Scientific, CA, USA), Chaer-specific siRNA (siChaer; 5′-CCCGGACUUAAAUAGUAUAU-3′; designed and synthesized by Bioland Scientific) and Hotair-specific siRNA (siHotair; GS10050387; Qiagen, Limburg, the Netherlands) were transfected into NRVMs using Lipofectamine RNAiMAX (Life Technologies). A 1.7-kb-long human CHAER homolog was cloned using Zero Blunt TOPO PCR cloning kit (Thermo Fisher Scientific, MA, USA), transferred into pcDNA5-CMV using BamHI and XhoI, and transfected into NRVMs and hiPSC-CMs using nanoparticle-mediated transfection reagents (Altogen Biosystems, NV, USA), according to the manufacturer's instructions. NRVMs or MEFs were infected with Ad-Chaer (10 7 plaque-forming units (PFU)/ml) for overexpression; the same amount of Ad-lacZ was used as a control. Phenylephrine (PE, 50 µM) was used to induce hypertrophy in NRVMs. NRVM starvation was performed by incubating the cells in branched-chain amino acid-depletion medium (Thermo Fisher Scientific) overnight, followed by re-feeding with normal culture medium.
Generation of Chaer-knockout mice. Chaer-knockout mice were generated using a CRISPR genome-editing system in the C57BL/6 background as previously reported 60 . A pair of single guide RNAs (sgRNAs) flanking exon 2 of Chaer (the majority of the lncRNA) was designed using an online CRISPR design tool (http://tools.genomeengineering.org) and inserted into the vector pUC57-sgRNA (Addgene). The sgRNAcoding DNA was then amplified together with the T7 promoter to generate pure templates for in vitro transcription using MEGA shortscript Kit (Life Technologies, NY, USA). A Cas9 expression plasmid (Addgene) was linearized with PmeI and used as template for in vitro transcription using the T7 Ultra Kit (Life Technologies). Purified Cas9 mRNA and sgRNAs were mixed and injected into the cytoplasm of fertilized eggs (with clearly evident pronuclei) of C57BL/6 mice in M2 medium (Sigma-Aldrich, MO, USA). Successful knockout was validated by PCR analysis with the following primers: Chaer WT-F: 5′-TGAACGCTCTGCAAATCCTA-3′; Chaer WT-R: 5′-TAAAGCCAGCAAGAACATAAGG-3′; Chaer KO-F: 5′-GGACAGCATCTTCCCTACCACC-3′; Chaer KO-R: 5′-CAACCAGTT GGAAGGCCGTAAG-3′. The wild-type allele yielded an amplicon of 155 bp, whereas the mutated allele yielded an amplicon of 317 bp. Out of 26 injected embryos, nine pups were generated and the mutated allele was detected in six. One mouse was selected to mate with the wild-type C57BL/6 strain to obtain F1-generation mice. Heterozygous F1 offspring were interbred to establish the Chaer −/− strain.
Transaortic constriction surgery and pressure-volume loop analysis.
Transaortic constriction (TAC) surgery was performed as described 22 . Wildtype and Chaer-KO male mice at 2 months of age were randomly separated into sham and TAC groups; group information was double blinded between the investigator who performed the surgery and the data analyzer. The mouse was fixed in a supine position with the neck slightly extended. A 20-G catheter was inserted through the larynx into the trachea with care taken not to puncture the trachea or other structures in the pharyngeal region (endotracheal incubation). Ventilation was performed with a tidal volume of 200 µL, respiratory rate of 120/min, 95% oxygen. Body temperature was maintained as close as possible to 37.0 °C throughout the experiment using a self-regulating heating pad. After disinfection with 2% iodine, the chest cavity was opened by an incision of the left second intercostal space. The aortic arch was dissected from the surrounding tissue. The pericardial sac was opened while a 6-0 suture was passed underneath the transverse aorta and ligated over a 27-G needle, which was removed later to provide a lumen. The chest cavity, muscle and skin were closed layer by layer. Sham-operated mice underwent similar surgical procedures, including isolation of the aorta and looping of the aorta, but without tying of the suture. Mice were observed until recovery in a 37.0 °C heated cage.
For the invasive hemodynamic analysis, mice were anesthetized by treatment with 1.5-2% isoflurane, and then a 1.4-FrenchMillar catheter-tip micromanometer catheter (SPR-839; Millar Instruments, Houston, Texas) was inserted through the right carotid artery into the left ventricle of the mice. After stabilization for 15 min, heart rate, pressure and volume signals were recorded continuously with an Aria pressure-volume conductance system coupled to a Powerlab/4SP A/D converter and subsequently were stored and displayed on a computer. Echocardiography. Transthoracic ultrasonography was performed with a Vevo 2100 system (Fujifilm VisualSonics, Ontario, Canada). Echocardiography was performed before and 4 d after TAC surgery. The inhalational flow of isoflurane was adjusted to anaesthetize the mice while maintaining their heart rate at 450-550 beats/min. The peak aortic blood velocity across the aortic constriction was measured in the pulsed-wave color Doppler mode. Left ventricular function was assessed by M-mode scanning of the left ventricular chamber, standardized by two-dimensional, short-axis views of the left ventricle at the mid papillary muscle level. Left ventricular chamber size and wall thickness were measured for at least three beats from each projection and averaged. Left ventricular internal dimensions at diastole and systole (LVID;d and LVID;s, respectively) were measured.
In vivo Chaer silencing. For in vivo gene knockdown, chemically modified siChaer (5′-CCGGACUUGAAUAGUAUAU-3′) and siNeg (CMSINC-30) were designed and synthesized by Bioland Scientific (CA, USA) and delivered into the heart using nanoparticle transfection reagent (Altogen Biosystems, NV, USA) by two injections through the femoral vein each day before (protocol 1) or after (protocol 2) TAC surgery, following the manufacturer's instructions 41 . The efficiency of Chaer knockdown in the heart was evaluated by real-time RT-PCR.
Northern blot analysis. Northern blot was performed with the DIG Northern
Starter Kit (12039672910, Roche). Briefly, total RNA was extracted from tissues using TRIzol reagents. RNA was quantified by spectrophotometry (NanoDrop 2000 spectrophotomoter, Thermo Fisher Scientific, MA, USA) and 1 µg RNA was combined with 4 µl formaldehyde, 10 µl deionized formamide and 2 µl npg
